Adjuvant S‐1 vs gemcitabine for node‐positive perihilar cholangiocarcinoma: A propensity score‐adjusted analysis

Background The efficacy of adjuvant chemotherapy for biliary cancers remains controversial because of conflicting results from previous phase 3 studies that used different key drugs and enrolled patients with heterogeneous tumor sites and disease stages. Fluoropyrimidine seems more beneficial than g...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepato-biliary-pancreatic sciences 2021-09, Vol.28 (9), p.716-726
Hauptverfasser:	Takahashi, Daigoro, Mizuno, Takashi, Yokoyama, Yukihiro, Igami, Tsuyoshi, Yamaguchi, Junpei, Onoe, Shunsuke, Watanabe, Nobuyuki, Maeda, Osamu, Ando, Masahiko, Ebata, Tomoki
Format:	Artikel
Sprache:	eng
Schlagworte:	adjuvant therapy Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - surgery Chemotherapy Chemotherapy, Adjuvant Cholangiocarcinoma Cholangiocarcinoma - drug therapy Deoxycytidine - analogs & derivatives gemcitabine Humans Klatskin Tumor - drug therapy Klatskin Tumor - surgery perihilar cholangiocarcinoma Propensity Score Retrospective Studies S‐1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!